Conjugated drug payload

A conjugated drug payload is the active pharmacological component of a targeted therapeutic, most commonly an Antibody-Drug Conjugate (ADC). It is a highly potent molecule, often too toxic for systemic administration on its own, that is chemically tethered to a targeting agent like a monoclonal antibody via a linker [1]. The primary biological function of the payload is to induce cell death or modulate a specific pathway within a target cell after the conjugate has bound to its surface antigen and been internalized [2]. Common payloads include microtubule-disrupting agents like auristatins and maytansinoids, or DNA-targeting agents like calicheamicins and camptothecin analogs [3]. These molecules are selected for their extreme potency, often in the picomolar range, to ensure efficacy even with limited antigen expression or internalization [4]. While the payload is the effector of the drug's action, it is not a biological target itself; rather, it is the warhead delivered to a specific site to treat diseases such as cancer [1].

Other names

Cytotoxic payloadWarheadEffector moleculeADC payloadSmall molecule payload

Conjugated drug payloads exert their effects by inducing cell death through various mechanisms once released from the targeting moiety. These include the inhibition of tubulin polymerization, which disrupts the mitotic spindle and causes cell cycle arrest, or the induction of DNA damage through alkylation, intercalation, or inhibition of topoisomerase enzymes, leading to apoptosis [1][2].